<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366365">
  <stage>Registered</stage>
  <submitdate>19/05/2014</submitdate>
  <approvaldate>6/06/2014</approvaldate>
  <actrnumber>ACTRN12614000610639</actrnumber>
  <trial_identification>
    <studytitle>Recruitment of brown fat in overweight adult humans with high blood pressure</studytitle>
    <scientifictitle>The effect of telmisartan treatment on brown adipose tissue (BAT) in overweight hypertensive humans</scientifictitle>
    <utrn />
    <trialacronym>ROBIN</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension</healthcondition>
    <healthcondition>Overweight</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: change from usual blood pressure medication to  telmisartan 40-80 mg daily (therapeutic dosage) orally for 4 weeks. Adherence will be monitored by drug tablet return.

 
</interventions>
    <comparator>Arm 2 (active comparator): change from usual medication to candesartan 8-16 mg daily (therapeutic dosage) orally for 4 weeks. Adherence will be monitored by drug tablet return.

Arm 3 (control): continue usual blood pressure medication</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Brown fat abundance and activity by Positron Emission Tomography (PET)/Computerised Tomography (CT)</outcome>
      <timepoint>Four weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Glucose tolerance by oral glucose tolerance test</outcome>
      <timepoint>Four weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Insulin sensitivity by oral glucose tolerance test</outcome>
      <timepoint>Four weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition by dual energy X-ray absortiometry </outcome>
      <timepoint>Four weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. BMI: 20-30 kg/m2
2. Disease status: uncomplicated hypertension on mono-therapy (ACE inhibitor or calcium channel blockers (CCB)) with stable blood pressure control for &gt; 6 months.
3. Willingness to give written informed consent and willingness to participate to and comply with the study
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>* BMI &lt;20 or &gt;30 Kg/m2. 
* Age &lt;18 or &gt;45 years old. 
* Pregnant or breast-feeding.
* History/laboratory (screening test) evidence of significant cardiovascular, endocrine, neoplastic, renal, hepatic or metabolic disorders, including hyperkalaeamia.  
* On more than 1 anti-hypertensive medication.
* Known hypersensitivity to any angiotensin receptor blocker.
* Current diabetes medication therapy (however, patients with pre-diabetes or diet-controlled diabetes not on medication may participate) 
* On therapies with possible effects on brown fat and or glycemia (e.g. beta-agonists (including inhaled formulations), beta-blockers, alpha-blockers, diuretics, glucocorticoids and/or hormone replacement).
* Unwillingness to undergo blood pressure monitoring during treatment phase.
* Claustrophobia.
* History of illicit drug or alcohol abuse within the last 5 years; current use of drugs (by history) or alcohol (CAGE score&gt;3).
* Inability to provide written informed consent
* Current use of medications/dietary supplements/alternative therapies known to alter endocrine/metabolic function.
* Current use of antiplatelet or anticoagulants (if subjects decide to participate in optional tissue biopsies).
* Current smoker or user of tobacco products
* Current participation in weight loss programs (dietary, exercise or pharmacological) or more than 3 kg weight changes in last 6 months 

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>Sample size calculation: The primary endpoint is the change in BAT volume and activity before and after telmisartan treatment. Based on known improvement in insulin sensitivity by ~20% (which we hypothesize to correlate with BAT recruitment), a sample size of 16 subjects per group (taken into account 20% drop out) has 80% power to detect a difference in BAT of 10%, as guided by a BAT prevalence of ~50% in overweight individuals. 
Analysis plan: Changes in BAT and glucose metabolism before and after treatment will be analysed with treatment effect in mixed model analyses.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>16/06/2014</anticipatedstartdate>
    <actualstartdate>7/07/2014</actualstartdate>
    <anticipatedenddate>1/06/2015</anticipatedenddate>
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital (Darlinghurst) - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Garvan Institute of Medical Research</primarysponsorname>
    <primarysponsoraddress>384 Victoria Street, Darlinghurst, NSW 2010 </primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council </fundingname>
      <fundingaddress>National Health and Medical Research Council GHD Building Level 1, 16 Marcus Clarke St, Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Diabetes Australia</fundingname>
      <fundingaddress>Diabetes Australia
570 Elizabeth Street
Melbourne  VIC  3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>St Vincent's Hospital, Sydney</sponsorname>
      <sponsoraddress>380 Victoria Street, Darlinghurst, NSW 2010</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary aim of the study is to investigate the impact of telmisartan treatment on brown fat in humans. The hypothesis is that telmisartan recruits brown fat in humans, thereby improving glucose metabolism.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>St Vincent's Research Office
Level 6 deLacy Building
380 Victoria Street
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>13/05/2014</ethicapprovaldate>
      <hrec>HREC/13/SVH/377</hrec>
      <ethicsubmitdate>31/03/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Paul Lee</name>
      <address>Garvan Institute of Medical Research
Clinical Diabetes and Metabolism
384 Victoria Street
Darlinghurst
NSW 2010</address>
      <phone>+61 2 9295 8416</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Paul Lee</name>
      <address>Garvan Institute of Medical Research
Clinical Diabetes and Metabolism
384 Victoria Street
Darlinghurst
NSW 2010</address>
      <phone>+61 2 9295 8416</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Paul Lee</name>
      <address>Garvan Institute of Medical Research
Clinical Diabetes and Metabolism
384 Victoria Street
Darlinghurst
NSW 2010</address>
      <phone>+61 2 9295 8416</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Paul Lee</name>
      <address>Garvan Institute of Medical Research
Clinical Diabetes and Metabolism
384 Victoria Street
Darlinghurst
NSW 2010</address>
      <phone>+61 2 9295 8416</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>